Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. - Wikidata - awgldk - TriplyDB

Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

http://www.wikidata.org/entity/Q44513209

about

Stable isotope-resolved metabolomics and applications for drug development The Utility of Metabolic Imaging by 18F-FDG PET/CT in Lung Cancer: Impact on Diagnosis and Staging The use and misuse of positron emission tomography in lung cancer evaluation Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures.Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).Positron emission tomography/computerized tomography in lung cancer.PET/CT in Oncology: Current Status and Perspectives.Quantitative measurement of organic acids in tissues from gastric cancer patients indicates increased glucose metabolism in gastric cancer.Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer Imaging in clinical trials.Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target.Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT.FDG-PET in colorectal cancer.Comparison of texture features derived from static and respiratory-gated PET images in non-small cell lung cancer Integrin alpha v beta 3-targeted imaging of lung cancer.Prediction of response by FDG PET early during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.18F-FDG PET/CT imaging in oncology Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal Cancer Cancer associated fibroblasts in hematological malignancies.Functional imaging in lung cancer Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers.Medical imaging in new drug clinical development.Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.Pulmonary subsolid nodules: what radiologists need to know about the imaging features and management strategy.Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.Role of FDG-PET in the diagnosis and management of lung cancer.Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells.Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study.A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment.Metabolic response assessment with (18)F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer.Does early PET/CT assesment of response to chemotherapy predicts survival in patients with advanced stage non-small-cell lung cancer?Noise considerations for PET quantification using maximum and peak standardized uptake value.Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery.18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.Personalised medicine for cancer: from drug development into clinical practice.FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy Computerized PET/CT image analysis in the evaluation of tumour response to therapy.Promise and pitfalls of quantitative imaging in oncology clinical trials.

P2860

Q24629149-5580D293-9C88-4A7C-AC86-8171DCC4B5FB Q27001239-590877A7-317A-4051-8B2E-44227009B4A9 Q27021838-3F7AAE1E-5BFD-4324-B3B9-8F2730D6B6A2 Q30645097-0ADBDB82-63A9-48C2-9B10-0EABA7F1B1D8 Q33392707-FAD6F01A-3C38-4AC9-87A4-8C6A00CE5DC4 Q33657999-A2039386-18E7-4960-BC33-DDADADF6A72C Q33665109-A377E10E-8036-4C0C-9F57-29A6411C8C0A Q33727137-47B7BA76-9FAB-4029-B582-FE136CEF9319 Q33806271-DBF32E40-4331-49BF-9292-AB2F61C8E346 Q34203953-E3F2B986-8405-47D3-9D91-3FF867A03E81 Q34243500-3A5711E4-754B-4242-8651-691D01A4021D Q34256382-6A531525-12C4-4ECF-9D63-3CC1F7F8FD1C Q34310486-9729E495-6328-4E12-A7D6-A77EE4A43FE0 Q34336023-7406192C-AEDB-4ED4-89CD-220CEC224DDE Q34572647-3246A4E4-E342-466C-9D79-39F11C1E1166 Q34724752-158B962B-47EC-4C00-AD13-3CE30FA731E6 Q34768362-5AFBC462-E9E3-4997-85FE-BB3C62ADAA92 Q34810709-984E95AF-10B8-45C3-BD70-7EFBEB926D05 Q35006097-51744C1D-F4E3-4F3E-8DE6-743B0496C088 Q35445146-1DC42F9D-706F-452C-98EA-62A4DF03CCD0 Q35550041-98DA6510-7E46-4EFB-A997-FEEFE8E0DAF0 Q35550676-D6258E3B-2039-4F54-B284-1544AA956CB5 Q35583933-0FF8BA29-7FED-4F18-8A8F-ED55045EEC38 Q35667744-3C652CBC-3ADF-405B-BF65-6C6864BF58B7 Q35675442-5B2E52E5-441C-4E63-8776-C33452D23D36 Q35720347-EF9EB4A9-28BC-49F6-9E40-F0D5C7A2D8DF Q35761121-DA090AF1-ED5C-4964-9482-8F24A291EB5D Q35843677-7A71F576-B3F3-4369-8421-6357D7E064D2 Q36012091-DCE1B99A-D954-4880-9FF3-5ADC39D1FD87 Q36014679-F8DCD1A0-5500-4F7E-8514-B01B4F93323E Q36021562-96FFD4FB-7E7B-4B28-9BE6-25429DBFF4CC Q36024114-90698921-C1CD-492A-B728-1044C1F2DFD9 Q36154024-EA2143E1-F4F5-4184-BA67-4AD06C058942 Q36158583-1FB69B10-B3DB-4138-91FC-6EF5871DE498 Q36194573-380ECCBE-7EF1-4130-AEF8-AB5766F37F68 Q36201687-59FE6833-D667-4EE7-983C-A552C8EBD2CD Q36221957-073EAED8-C21E-4422-B998-E1241690337F Q36239986-647E6C6E-61C9-49CE-91C4-C25917BAE434 Q36295403-1780B20E-0BBE-43C4-91D2-CABC2429B775 Q36303765-B337694A-9E48-4494-9BC1-ACBF78825A74

P2860

Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

http://www.wikidata.org/entity/Q44513209

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Positron emission tomography i ...... ive assessment of glucose use.

@en

Positron emission tomography i ...... ive assessment of glucose use.

@nl

type

label

Positron emission tomography i ...... ive assessment of glucose use.

@en

Positron emission tomography i ...... ive assessment of glucose use.

@nl

prefLabel

Positron emission tomography i ...... ive assessment of glucose use.

@en

Positron emission tomography i ...... ive assessment of glucose use.

@nl

P1433

Q44513209-8DE35EF8-37A5-4BE5-AFB0-761F811EC40C

P1476

Q44513209-5AF68710-F82F-4301-ABA0-BB0C8CE31510

P2093

Q44513209-0F6297A0-C03F-4483-A707-7348ED9C8A47

Q44513209-48B62163-3E28-4413-AFE7-A5E33D21BBF3

Q44513209-5C0D2C9C-6E30-47F5-8964-89B155F3F21A

Q44513209-9C6EA920-AF10-4934-AC04-04BF2A01C502

Q44513209-AD5FD0D7-6546-4973-B316-6D928FEAA4CF

Q44513209-AE74D8E6-364A-4CB2-80DC-53D379D48BE7

P304

Q44513209-076D2D51-AEE1-4F8E-A5FC-61E86FB41D97

P31

Q44513209-5877DCAF-3D79-46A1-B88F-8B64089B9A65

P356

Q44513209-B7E2D168-60C8-4BF4-8864-F933A11560D0

P407

Q44513209-B160EB3C-3147-4263-8265-00CC98896425

P433

Q44513209-1964FA77-1CF3-4BC1-BBB4-BD7B3B179735

P478

Q44513209-ABF0A643-54D9-4DD5-A8CE-F35977444F14

P50

Q44513209-B7957741-392A-47B9-A1A9-D4B60A5C5823

P577

Q44513209-3241974F-C7CE-4F22-BC53-D5869DF6B0A9

P698

Q44513209-C1FEE719-3966-42EA-AA2D-E99A9D3DAD3E

P921

Q44513209-17CA74C4-9EBA-4E75-964D-D0A66B599483

Q44513209-727E0B49-8877-402D-8F9F-28D385B280F1

Q44513209-7d9c5107-e1b5-4320-9811-8fef0c8d7f19

P356

JCO.2003.12.004

P1433

Journal of Clinical Oncology

P1476

Positron emission tomography i ...... ive assessment of glucose use.

@en

P2093

Burkhard Schmidt

http://www.w3.org/2001/XMLSchema#string

Christian Peschel

http://www.w3.org/2001/XMLSchema#string

Leishia Tyndale-Hines

http://www.w3.org/2001/XMLSchema#string

Thomas Link

http://www.w3.org/2001/XMLSchema#string

Volker Petersen

http://www.w3.org/2001/XMLSchema#string

Wolfgang A Weber

http://www.w3.org/2001/XMLSchema#string

P304

2651-2657

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.12.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Markus Schwaiger

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12860940

http://www.w3.org/2001/XMLSchema#string

P921